Pharming Group N.V. ADR PHAR 深 沪
等待开盘 09-18 09:30:00 美东时间
14.60
+0.700
+5.04%
华盛通- 最 高14.99
- 今 开14.21
- 成交量 1.12万股
- 最 低 14.21
- 昨 收 13.90
- 总市值 9.99亿
- 52周最高 17.08
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 7.31
- 委 比 -3.45%
- 总股本 6839.31万
- 历史最高 21.99
- 量 比 0.68
- 振 幅 5.61%
- 历史最低 6.10
- 每 手 1
- 风险率 1.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pharming Group promoted to the Euronext AMX® index
Pharming Group N.V. has been promoted to the Euronext AMX (MidCap) index, effective September 22, 2025, reflecting its strong growth momentum. The company, which focuses on rare diseases, aims to enhance visibility and attract investors, supporting its goal of becoming a leading global rare disease company.
09-10 05:00
Sun Pharma’s Halol Facility Faces FDA Compliance Challenges
Sun Pharmaceutical Industries Limited ( ($IN:SUNPHARMA) ) has provided an updat...
09-09 23:23
Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference
Pharming Group N.V. will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8-10, 2025. Fabrice Chouraqui, CEO, will present on September 8 at 1:30pm EDT. The presentation will be available live and on replay via Pharming’s website. Pharming is a global biopharmaceutical company focused on advancing treatments for rare diseases, with operations spanning over 30 markets worldwide. For further infor...
09-03 06:00
Pharming Group names new finance head
Pharming Group (PHAR) appointed Kenneth Lynard as CFO, effective October 1, 2025. Mr. Lynard is a seasoned finance executive with over 20 years of global leadership experience in the life sciences i...
09-02 16:25
Pharming Group appoints Kenneth Lynard as Chief Financial Officer
Pharming Group N.V. announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective October 1, 2025. Mr. Lynard, with over 20 years of global leadership experience in the life sciences industry, will strengthen the company's financial leadership as it continues to execute its growth strategy. His experience includes roles at Schoeller Allibert and Zentiva, Affidea, and Gilead Sciences, where he contributed to significant b...
09-02 05:00
CLINUVEL Plans Nasdaq Uplisting to Boost U.S. Market Presence
Clinuvel Pharmaceuticals ( ($AU:CUV) ) just unveiled an update. CLINUVEL PHARMA...
08-22 09:37
Piramal Pharma Completes Major Financial Transaction
An update from Piramal Pharma Limited ( ($IN:PPLPHARMA) ) is now available. Pir...
08-21 00:19
百济神州上半年：扭亏为盈狂揽175亿
8月6日，百济神州公布2025年第二季度美股业绩报告以及A股2025年半年度主要财务数据公告。2025年上半年，百济神州实现营业总收入175.18亿元，同比增长...
08-07 10:15
Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date
NASHVILLE, Tenn., Aug. 5, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved ...
08-06 04:05
